Nu Skin Enterprises Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
|
||
Date of Report (Date of earliest event reported)
|
|
||
(Exact name of registrant as specified in its charter)
|
|
|
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
||
(Address of principal executive offices and zip code)
|
(
|
||
(Registrant’s telephone number, including area code)
|
N/A
|
||
(Former name or former address, if changed since last report)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
Item 2.01
|
Completion of Acquisition or Disposition of Assets.
|
Item 7.01
|
Regulation FD Disclosure.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
Exhibit No.
|
Description
|
|
Unit Purchase Agreement, dated as of January 2, 2025, by and among Mavely Seller LLC, Mavely LLC, Clout.io Holdings, Inc. and Mavrck LLC.
|
||
Press Release, dated as of January 3, 2025.
|
||
Unaudited Pro Forma Condensed Consolidated Financial Information.
|
||
104
|
Cover Page Interactive Data File (formatted as Inline XBRL).
|
• |
the net proceeds to be retained by the Company and its subsidiaries in connection with the closing of the Mavely Transaction are subject to adjustments as set forth in the Purchase Agreement, including post-closing determination of working capital and other elements of the purchase price, which may reduce the amount of consideration to be retained by the
Company and its subsidiaries;
|
• |
risk that the Purchaser, Mavrck, and Mavely companies may encounter difficulties integrating their businesses or achieving the synergies that are anticipated from the transaction, or risks
associated with not providing services to the company as currently anticipated;
|
• |
any failure of current or planned initiatives or products to generate interest among the Company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;
|
• |
risk that direct selling laws and regulations in any of the Company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in
negative changes to the Company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of
fines, or any other adverse actions or events;
|
• |
economic conditions and events globally;
|
• |
competitive pressures in the Company’s markets;
|
• |
risk that epidemics, including COVID-19 and related disruptions, or other crises could negatively impact our business;
|
• |
adverse publicity related to the Company’s business, products, industry or any legal actions or complaints by the Company’s sales force or others;
|
• |
political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
|
• |
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and
results;
|
• |
risk of foreign-currency fluctuations and the currency translation impact on the Company’s business associated with these fluctuations;
|
• |
uncertainties regarding the future financial performance of the businesses the Company has acquired;
|
• |
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs
if the Company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
|
• |
regulatory risks associated with the Company’s products, which could require the Company to modify its claims or inhibit its ability to import or continue selling a product in a market if the
product is determined to be a medical device or if the Company is unable to register the product in a timely manner under applicable regulatory requirements; and
|
• |
the Company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the Company’s products imported into the Company’s markets outside of the United
States, and any adverse results of tax audits or unfavorable changes to tax laws in the Company’s various markets.
|
NU SKIN ENTERPRISES, INC.
|
||
(Registrant)
|
||
/s/ James D. Thomas
|
||
James D. Thomas
|
||
Chief Financial Officer
|
||
Date: January 3, 2025
|